01GROUNDED
Guideline-backed rule engine
CYP-genotype screening built on CPIC and PharmVar, paired with curated drug–drug interaction flagging. Deterministic, reproducible, and resolved with zero ambiguity.
Clinical decision support · pharmacogenomics + polypharmacy
Prescribe to the patient, not the average.
Genotype-aware prescribing and drug-interaction screening, delivered at the moment of decision — so every flag carries the clinical evidence behind it, in one structured report.
The scale of the problem
Every number below is a published estimate. Sources cited at the bottom of the page.
0.0M+1
per year
U.S. ED visits for adverse drug events
0%2
of hospital admissions
are caused by an adverse drug reaction
0%3
of commonly prescribed drugs
are metabolized by CYP450 enzymes
0%4
of ADRs avoided
with pre-emptive pharmacogenetic testing
More than 94% of people carry at least one actionable pharmacogenetic variant5, yet the vast majority are prescribed without ever being genotyped. The gap is not subtle — it is the default.
The comparison
Same patient. Two different outcomes.
Legacy prescribing asks: does this drug fit the diagnosis? Genotype- and interaction-aware prescribing asks: does it fit this patient? Toggle to compare.
Same patient, two workflows
Ms. K, 62— hypertension, anxiety, post-op pain
Proposed regimen
- codeine 30mg q6h prn(post-op pain)
- fluoxetine 20mg daily(anxiety)
Legacy prescribing
Blind to genotype. DDI checks manual or absent.
- CYP2D6 phenotype
- unknown
- DDI with current meds
- not checked
- Morphine exposure (codeine)
- assumed typical
Adverse-event likelihoodHigh
Prescribed as written
Ms. K is a CYP2D6 ultrarapid metabolizer on fluoxetine — opioid exposure and serotonergic toxicity risk both missed.
Try it
Polypharmacy grows combinatorially.
Drag the slider. Adding a single medication adds n new interaction pairs — the surface area for harm compounds faster than most prescribers expect.
3drug pairs
Concurrent medications
3drugs
Interaction risk
Moderate
1510
Pairwise combinations grow as n(n−1)/2. At 3 drugs, roughly 0.6 of the 3 possible pairs are expected to carry a clinically meaningful interaction. Illustrative, not a clinical prediction.
Clinical guidelines. Transparent intelligence.
Two layers, one report. Every flag is grounded in a published guideline — and every guideline is visible on the same line.
02TRANSPARENT
Source-visible intelligence
An intelligence layer surfaces mechanism, management, and severity for every finding — each one annotated with the exact citation that backs it, never composed from outside the evidence.